# A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014)

> **NCT06821334** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 37 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** MK-6194
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06821334
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-23
- **Primary completion:** 2024-08-09
- **Final completion:** 2024-08-09
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2025-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06821334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06821334, "A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06821334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*